Compare TCBS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBS | NSRX |
|---|---|---|
| Founded | 1934 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 53.5M |
| IPO Year | 2021 | N/A |
| Metric | TCBS | NSRX |
|---|---|---|
| Price | $16.65 | $4.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | 1.5K | ★ 2.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.01 | $3.99 |
| 52 Week High | $20.00 | $9.99 |
| Indicator | TCBS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 47.22 |
| Support Level | $15.69 | $3.99 |
| Resistance Level | $16.69 | $6.39 |
| Average True Range (ATR) | 0.23 | 0.42 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 18.92 | 61.65 |
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.